{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T11:43:16Z","timestamp":1788090196573,"version":"build-2803163510"},"reference-count":12,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,5,21]]},"DOI":"10.7759\/cureus.109348","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:44:58Z","timestamp":1779367498000},"source":"Crossref","is-referenced-by-count":1,"title":["Pembrolizumab and Enfortumab-Induced Immunotherapy Myocarditis"],"prefix":"10.7759","author":[{"given":"Chirag","family":"Lodha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J","family":"Basile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corbin C","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer","volume":"390","author":"Powles T","year":"2024","unstructured":"Powles T, Valderrama BP, Gupta S, et al.. Enfortumab vedotin and pembrolizumab in untreated advanced urothelial cancer. N Engl J Med. 2024, 390:875-88. 10.1056\/NEJMoa2312117","journal-title":"N Engl J Med"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.119.013757","article-title":"Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment","volume":"9","author":"Palaskas N","year":"2020","unstructured":"Palaskas N, Lopez-Mattei J, Durand JB, Iliescu C, Deswal A. Immune checkpoint inhibitor myocarditis: pathophysiological characteristics, diagnosis, and treatment. J Am Heart Assoc. 2020, 9:e013757. 10.1161\/JAHA.119.013757","journal-title":"J Am Heart Assoc"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1597259","article-title":"Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review","volume":"16","author":"S\u00e1nchez-Camacho A","year":"2025","unstructured":"S\u00e1nchez-Camacho A, Torres-Zurita A, Gallego-L\u00f3pez L, et al.. Management of immune-related myocarditis, myositis and myasthenia gravis (MMM) overlap syndrome: a single institution case series and literature review. Front Immunol. 2025, 16:9. 10.3389\/fimmu.2025.1597259","journal-title":"Front Immunol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.19102\/icrm.2025.16033","article-title":"Immune checkpoint inhibitor-induced myocarditis: a case report of complete heart block and challenges in a patient on pembrolizumab","volume":"16","author":"Panchal V","year":"2025","unstructured":"Panchal V, Momin E, Jain S, Singh A, Ghuman G, Brar V. Immune checkpoint inhibitor-induced myocarditis: a case report of complete heart block and challenges in a patient on pembrolizumab. J Innov Card Rhythm Manag. 2025, 16:6215-9. 10.19102\/icrm.2025.16033","journal-title":"J Innov Card Rhythm Manag"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.e16567","article-title":"Toxicity profile of enfortumab vedotin with or without pembrolizumab in patients with metastatic urothelial carcinoma: a systematic review and meta-analysis","volume":"43","author":"Sim\u00f5es CA","year":"2025","unstructured":"Sim\u00f5es CA, Asbeg N, Santos ACFdF, Cavalcante D, de Jesus ACVdS, Gazzoni G, Stecca C. Toxicity profile of enfortumab vedotin with or without pembrolizumab in patients with metastatic urothelial carcinoma: a systematic review and meta-analysis. J Clin Oncol. 2025, 43:7. 10.1200\/JCO.2025.43.16_suppl.e16567","journal-title":"J Clin Oncol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009475","article-title":"Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1\/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab","volume":"12","author":"Cavalcante L","year":"2024","unstructured":"Cavalcante L, Chandana S, Lakhani N, et al.. Case report of fatal immune-mediated myocarditis following treatment with davoceticept (ALPN-202), a PD-L1-dependent CD28 costimulator and dual PD-L1\/CTLA-4 checkpoint inhibitor, in combination with pembrolizumab. J Immunother Cancer. 2024, 12:5. 10.1136\/jitc-2024-009475","journal-title":"J Immunother Cancer"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/ehjcr\/ytaf019","article-title":"Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report","volume":"9","author":"Wadden E","year":"2025","unstructured":"Wadden E, Lai C, Grivas P, et al.. Successful treatment of immune checkpoint inhibitor-associated fulminant myocarditis with abatacept and ruxolitinib: a case report. Eur Heart J Case Rep. 2025, 9:ytaf019. 10.1093\/ehjcr\/ytaf019","journal-title":"Eur Heart J Case Rep"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1646040","article-title":"Successful ECMO support for cardiogenic shock induced by immune checkpoint inhibitor-associated myocarditis: a case report and literature review","volume":"16","author":"Zhang Y","year":"2025","unstructured":"Zhang Y, Li R, Jiang Y, Sun S, Yuan Y, Shang Y, Shu H. Successful ECMO support for cardiogenic shock induced by immune checkpoint inhibitor-associated myocarditis: a case report and literature review. Front Immunol. 2025, 16:1646040. 10.3389\/fimmu.2025.1646040","journal-title":"Front Immunol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccas.2025.105543","article-title":"Successful use of ruxolitinib for steroid-refractory immune checkpoint inhibitor-associated myocarditis","volume":"30","author":"Vockenhuber T","year":"2025","unstructured":"Vockenhuber T, Baldinger L, Clausen J, et al.. Successful use of ruxolitinib for steroid-refractory immune checkpoint inhibitor-associated myocarditis. JACC Case Rep. 2025, 30:105543. 10.1016\/j.jaccas.2025.105543","journal-title":"JACC Case Rep"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.12890\/2024_005003","article-title":"Severe cutaneous toxicity in a 67-year-old patient with metastatic urothelial carcinoma undergoing therapy with enfortumab vedotin and pembrolizumab","volume":"11","author":"M\u00fcller B","year":"2024","unstructured":"M\u00fcller B, Curatolo R, Juratli HA, Husic A, Nehring J, Potlukova E, Kohler A. Severe cutaneous toxicity in a 67-year-old patient with metastatic urothelial carcinoma undergoing therapy with enfortumab vedotin and pembrolizumab. Eur J Case Rep Intern Med. 2024, 11:3. 10.12890\/2024_005003","journal-title":"Eur J Case Rep Intern Med"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1007\/s13691-024-00665-7","article-title":"An autopsy case of lung adenocarcinoma with immune checkpoint inhibitor-induced pneumonia and fulminant myocarditis following pembrolizumab administration: a case report","volume":"13","author":"Hashimoto T","year":"2024","unstructured":"Hashimoto T, Takahashi K, Ito K, et al.. An autopsy case of lung adenocarcinoma with immune checkpoint inhibitor-induced pneumonia and fulminant myocarditis following pembrolizumab administration: a case report. Int Cancer Conf J. 2024, 13:218-22. 10.1007\/s13691-024-00665-7","journal-title":"Int Cancer Conf J"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1161\/circ.148.suppl_1.16013","article-title":"Abstract 16013: non-bacterial thrombotic endocarditis and recurrent cerebrovascular accidents in immune checkpoint inhibitor myocarditis","volume":"148","author":"Mitrani L","year":"2023","unstructured":"Mitrani L, Jou S, Mendez S, Song C, Yoon J, Dangayach NS, Sahni G. Abstract 16013: non-bacterial thrombotic endocarditis and recurrent cerebrovascular accidents in immune checkpoint inhibitor myocarditis. Circulation. 2023, 148:3. 10.1161\/circ.148.suppl_1.16013","journal-title":"Circulation"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/482896-pembrolizumab-and-enfortumab-induced-immunotherapy-myocarditis","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T12:44:59Z","timestamp":1779367499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/482896-pembrolizumab-and-enfortumab-induced-immunotherapy-myocarditis"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,21]]},"references-count":12,"URL":"https:\/\/doi.org\/10.7759\/cureus.109348","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5,21]]}}}